Biofrontera

Biofrontera FCF Margin

The Free Cash Flow Margin of Biofrontera (B8FK.DE) as of Nov 21, 2026 is -33.75 %. In the previous year, Free Cash Flow Margin was -22.56 % — a change of 49.56% (lower).

FCF Margin

-33.75 %

YoY

49.56%

Last updated:

Free Cash Flow Margin of Biofrontera is 2025 -33.75 % . Free Cash Flow Margin of Biofrontera was 2024 -22.56 % . It decreases by 49.56% lower compared to the previous year.

The Biofrontera FCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Margin
Date
FCF Margin
Jan 1, 2018
-66.08 EUR
Jan 1, 2019
-111.14 EUR
Jan 1, 2020
-11.94 EUR
Jan 1, 2021
103.55 EUR
Jan 1, 2022
-18.94 EUR
Jan 1, 2023
-8.77 EUR
Jan 1, 2024
-22.56 EUR
Jan 1, 2025
-33.75 EUR
The Biofrontera FCF Margin history
YEARFCF MarginYoY
-33.75 %+49.56%
-22.56 %+157.22%
-8.77 %-53.70%
-18.94 %-118.29%
103.55 %-967.36%
-11.94 %-89.26%
-111.14 %+68.20%
-66.08 %-41.21%
-112.40 %-38.61%
-183.09 %-23.45%
-239.19 %-8.50%
-261.41 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biofrontera Stock analysis

What does Biofrontera do? Biofrontera AG generates revenue by developing, selling, and distributing dermatological drugs and medical cosmetics for skin care, protection, and treatment. The company markets its portfolio which includes Ameluz for the photodynamic therapy of actinic keratoses, the PDT lamp BF-RhodoLED used in conjunction with Ameluz treatment, and Belixos, a herbal dermatological cream for conditions such as insect bites, burns, neurodermatitis, and psoriasis. These products address the needs of patients and healthcare providers seeking treatments for skin diseases and regenerative care of damaged skin. The firm also engages in the clinical development of drug candidates to expand its future revenue streams. This includes BF-derm1, a tablet containing an inhibitor that blocks histamine synthesis to prevent allergic reactions, and BF1, a selective serotonin receptor agent aimed at preventing migraines. Through its five wholly owned subsidiaries, notably B, Biofrontera AG supports these development and distribution activities from its headquarters in Leverkusen, Nordrhein-Westfalen. Biofrontera is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biofrontera stock

Free Cash Flow Margin of Biofrontera is -33.75 % in 2025.

Free Cash Flow Margin of Biofrontera changed from -22.56 % to -33.75 %, representing a 49.56% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin Biofrontera since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's Biofrontera with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Biofrontera

All Key Metrics — Biofrontera